Inozyme PharmaINZY
INZY
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
100% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 17
84% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 19
18% more funds holding
Funds holding: 89 [Q3] → 105 (+16) [Q4]
5.51% less ownership
Funds ownership: 87.07% [Q3] → 81.56% (-5.51%) [Q4]
49% less capital invested
Capital invested by funds: $286M [Q3] → $145M (-$141M) [Q4]
53% less call options, than puts
Call options by funds: $7K | Put options by funds: $15K
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$11
1,008%
upside
Avg. target
$17.83
1,697%
upside
High target
$30
2,922%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Raymond James Ryan Deschner 78% 1-year accuracy 7 / 9 met price target | 1,109%upside $12 | Outperform Maintained | 12 Mar 2025 |
Piper Sandler Allison Bratzel 36% 1-year accuracy 4 / 11 met price target | 2,217%upside $23 | Overweight Maintained | 11 Mar 2025 |
Needham Joseph Stringer 24% 1-year accuracy 30 / 123 met price target | 1,411%upside $15 | Buy Maintained | 11 Mar 2025 |
HC Wainwright & Co. Edward White 32% 1-year accuracy 48 / 148 met price target | 1,512%upside $16 | Buy Reiterated | 11 Mar 2025 |
Piper Sandler Christopher Raymond 33% 1-year accuracy 10 / 30 met price target | 2,922%upside $30 | Overweight Maintained | 13 Jan 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights
- Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost savings from prioritizing ENPP1 Deficiency program, including an approximately 25% workforce reduction, expected to support operations into the first quarter of 2026 - - Enrollment complete in ENERGY 3 pivotal trial in pediatric patients with ENPP1 Deficiency; topline data expected in first quarter of 2026 - - Positive interim results from ENERGY 1 trial and Expanded Access Program evaluating INZ-701 in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease - BOSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today reported financial results for the full year ended December 31, 2024, and provided recent business highlights. "2024 marked a transformative year for Inozyme as we achieved critical milestones in our ENPP1 Deficiency program that enabled us to complete enrollment in our pivotal ENERGY 3 trial and announce promising interim data in infants and young children with ENPP1 Deficiency in January 2025," said Douglas A.
Neutral
GlobeNewsWire
1 month ago
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, from 1:10-1:40pm ET.
Neutral
GlobeNewsWire
1 month ago
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025
BOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer, will present recently announced data from the company's Expanded Access Program (EAP) evaluating INZ-701 in infants and children with ENPP1 Deficiency at the CHOP Cardiology Annual Meeting, held February 19-23, 2025, in Orlando, Florida.
Neutral
GlobeNewsWire
3 months ago
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 from 2:30-2:55pm ET.
Neutral
Zacks Investment Research
4 months ago
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks
Inozyme Pharma (INZY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Neutral
GlobeNewsWire
4 months ago
Inozyme Pharma to Present at Upcoming Investor Conferences
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the following investor conferences:
Neutral
GlobeNewsWire
4 months ago
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 –
Neutral
GlobeNewsWire
5 months ago
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with calciphylaxis, a rare, life-threatening complication of ESKD -
Neutral
GlobeNewsWire
5 months ago
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that interim data from the Company's ongoing Phase 1 SEAPORT 1 of INZ-701 in patients with end-stage kidney disease (ESKD) receiving hemodialysis will be presented during a poster session at the American Society of Nephrology (ASN) Kidney Week 2024, which is being held October 24-27, 2024, in San Diego.
Neutral
GlobeNewsWire
5 months ago
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced the appointment of Erik Harris to its Board of Directors, effective October 3, 2024. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings to Inozyme over 20 years of commercial expertise within the biopharma industry.
Charts implemented using Lightweight Charts™